Raiffeisen Bank International AG Has $27.36 Million Stake in Danaher Corporation $DHR

Raiffeisen Bank International AG reduced its stake in shares of Danaher Corporation (NYSE:DHR) by 12.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 136,116 shares of the conglomerate’s stock after selling 20,209 shares during the quarter. Raiffeisen Bank International AG’s holdings in Danaher were worth $27,359,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Boyd Watterson Asset Management LLC OH grew its stake in Danaher by 2.1% during the second quarter. Boyd Watterson Asset Management LLC OH now owns 2,524 shares of the conglomerate’s stock worth $499,000 after buying an additional 51 shares during the last quarter. Worth Financial Advisory Group LLC boosted its holdings in shares of Danaher by 4.6% in the 2nd quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate’s stock worth $236,000 after acquiring an additional 53 shares in the last quarter. 1834 Investment Advisors Co. grew its position in Danaher by 3.3% during the 1st quarter. 1834 Investment Advisors Co. now owns 1,666 shares of the conglomerate’s stock worth $342,000 after acquiring an additional 54 shares during the last quarter. Bruce G. Allen Investments LLC increased its holdings in Danaher by 13.1% during the 2nd quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate’s stock valued at $92,000 after purchasing an additional 54 shares in the last quarter. Finally, Texas Bank & Trust Co boosted its stake in Danaher by 1.6% in the second quarter. Texas Bank & Trust Co now owns 3,567 shares of the conglomerate’s stock worth $705,000 after purchasing an additional 55 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of Danaher stock opened at $221.25 on Monday. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $258.23. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. The stock has a market capitalization of $156.28 billion, a price-to-earnings ratio of 45.62, a PEG ratio of 3.28 and a beta of 0.81. The firm has a fifty day moving average of $205.63 and a two-hundred day moving average of $201.11.

Danaher (NYSE:DHR) last released its earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.17. The firm had revenue of $6.05 billion for the quarter, compared to analyst estimates of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The company’s quarterly revenue was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.71 earnings per share. As a group, equities research analysts predict that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Friday, September 26th were issued a $0.32 dividend. The ex-dividend date was Friday, September 26th. This represents a $1.28 annualized dividend and a yield of 0.6%. Danaher’s dividend payout ratio (DPR) is 26.39%.

Wall Street Analysts Forecast Growth

DHR has been the topic of several research reports. Wells Fargo & Company reiterated a “positive” rating on shares of Danaher in a research report on Thursday, October 23rd. UBS Group decreased their price target on shares of Danaher from $240.00 to $225.00 and set a “buy” rating on the stock in a research note on Wednesday, July 23rd. Royal Bank Of Canada set a $241.00 price objective on shares of Danaher in a research report on Tuesday, September 2nd. Wall Street Zen downgraded Danaher from a “buy” rating to a “hold” rating in a report on Monday, November 10th. Finally, Rothschild & Co Redburn reissued a “neutral” rating and issued a $220.00 target price (down from $245.00) on shares of Danaher in a research note on Wednesday, October 8th. Eighteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $243.39.

Insider Activity

In other news, SVP Brian W. Ellis sold 21,776 shares of the business’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total value of $4,773,952.48. Following the completion of the transaction, the senior vice president owned 14,553 shares of the company’s stock, valued at $3,190,454.19. The trade was a 59.94% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Georgeann Couchara sold 5,174 shares of the firm’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $210.42, for a total value of $1,088,713.08. Following the sale, the senior vice president directly owned 2,625 shares in the company, valued at $552,352.50. The trade was a 66.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 29,728 shares of company stock valued at $6,448,990 in the last quarter. Company insiders own 11.10% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.